Treatment for newly diagnosed CD19-positive mixed phenotype acute leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new treatment for adults with a rare type of leukemia that has both myeloid and lymphoid features and is positive for the CD19 marker. It aims to see if this treatment can help people who have not been treated yet for this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been newly diagnosed with mixed phenotype acute leukemia.
- Your leukemia cells are positive for CD19.
- You have not had certain prior treatments, like bevacizumab, CAR-T therapy, or other gene-modified cell therapies.
- You have not had any anti-tumor treatment (such as surgery, chemotherapy, or targeted therapy) within a certain period before starting this trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs — a Bcl-2 inhibitor (which helps leukemia cells die) and azacitidine (a medicine that helps the bone marrow make normal blood cells) — for people newly diagnosed with mixed phenotype acute leukemia. The goal is to see if this combination is safe and effective for this rare type of leukemia.
This early-phase trial tests an injected “CAR T” cell therapy made to attack CD19-positive blood cancers that have come back or did not respond. If you qualify, the study checks whether the treatment can help control the cancer and is safe enough to study further.
This trial tests a new drug called BEBT-908 combined with chemotherapy for adults with a specific type of acute lymphoblastic leukemia (ALL) who are in remission but still have small amounts of cancer cells (MRD positive). The goal is to see if this combination can get rid of those remaining cells and reduce the risk of relapse.
This trial tests a combination of immunotherapy (using the immune system to fight cancer) and chemotherapy in adults aged 15–65 with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL), a blood cancer. The goal is to see if this combination helps patients achieve remission and survive longer.
This trial tests a combination of a targeted drug and low-dose chemotherapy for adults newly diagnosed with a certain type of acute lymphoblastic leukemia (ALL). The goal is to find a gentler but effective treatment that may be easier for patients to tolerate.
This trial tests a combination of low-dose chemotherapy and immune-targeted drugs for adults newly diagnosed with a specific type of leukemia. The goal is to find a treatment that is effective with fewer side effects.
Hear when a new Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.